Gregory M. Glenn, President, R&D at NOVAVAX INC (NVAX), sold 14,400 shares at $166.78 ($2.3M) on 2021-10-12, disclosed to the SEC on 2021-10-14.
Open-market sale of $2.3M NVAX by President, R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $161.58 | 1,000 | $162K | 6.9% |
| 2 | $162.45 | 2,900 | $471K | 20.1% |
| 3 | $162.45 | 2,900 | $471K | 20.1% |
| 4 | $163.38 | 2,858 | $467K | 19.9% |
| 5 | $163.38 | 2,858 | $467K | 19.9% |
| 6 | $164.50 | 800 |
| $132K |
| 5.6% |
| 7 | $165.70 | 392 | $65K | 2.8% |
| 8 | $165.70 | 392 | $65K | 2.8% |
| 9 | $166.78 | 300 | $50K | 2.1% |
| Total | $163.14 avg | 14,400 | $2.3M | 100% |
| Filing → |
| NVAX | SELL | 2021-12-09 | $1.6M | — | Filing → |
| NVAX | SELL | 2021-12-02 | $3.2M | — | Filing → |
| NVAX | SELL | 2021-11-30 | $719K | — | Filing → |